Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual M...
May 17 2017 - 5:00PM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient enrichment,
today announced that safety and PK/PD data from its Phase 1 ICONIC
Study of JTX-2011, an agonist monoclonal antibody targeting ICOS,
will be presented in a poster presentation at the 2017 American
Society of Clinical Oncology (ASCO) Annual Meeting, taking place
June 2-6, 2017 in Chicago. Enrollment has been completed in both
the Phase 1 monotherapy and combination dose escalation cohorts,
and safety, PK and PD data from those patients will be presented at
the conference. In addition, a poster that illustrates Jounce’s
biomarker-driven approach to patient enrichment and provides
insights into the strategy employed in the Phase 2 portion of the
trial will be presented.
Poster Presentations Details:
Title: Biomarker-driven indication selection in
JTX-2011 ICONIC clinical trial
Presenter: Heather Anne Hirsch, associate
director of bioinformatics at Jounce Therapeutics Abstract
#: 11602 Session Title:
Tumor Biology Location: Hall A Poster
board #: 302 Date and
Time: Saturday, June 3, 2017; 1:45–4:45 p.m. CT
Title: Phase 1 safety of ICOS agonist antibody
JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors;
predicted vs observed pharmacokinetics (PK) in ICONIC
Presenter: Howard A. Burris, MD, chief
medical officer and president of Sarah Cannon Research Institute
Abstract #: 3033 Session
Title: Developmental Therapeutics—Immunotherapy
Location: Hall A Poster board
#: 128 Date and Time: Monday,
June 5, 2017; 8–11:30 a.m. CT
About the ICONIC StudyThe ICONIC study (ICOS
AgONist Antibody for Immunotherapy in Cancer Patients) is an open
label, dose-escalation and expansion clinical study of JTX-2011
alone or in combination with a fixed dose of nivolumab in subjects
with advanced solid tumors. The four-part, adaptive design includes
Parts A, B, C and D. Parts A and B comprise the Phase 1 portion of
the study and are designed to provide safety, PK and PD data in
both the monotherapy (Part A) and combination therapy (Part B)
settings. Parts C (monotherapy) and D (combination therapy) are
designed to provide preliminary efficacy proof-of-concept data. For
more information on the ICONIC trial, visit clinicaltrials.gov.
About JTX-2011Jounce’s lead product candidate,
JTX-2011, is a monoclonal antibody that binds to and activates
ICOS, a protein on the surface of certain T cells.
Preclinical data support that JTX-2011 may have a dual mechanism of
action that stimulates anti-tumor T effector cells, and also
reduces the immunosuppressive T regulatory cells in the tumor
microenvironment. The company is developing JTX-2011 to treat solid
tumors as a single agent and in combination with other
therapies.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long‑lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right therapy to the right patient. Jounce’s
lead product candidate, JTX-2011, is a monoclonal antibody that
binds to and activates ICOS and is currently in a Phase 1/2 trial.
For more information, please visit http://jouncetx.com/.
Forward Looking StatementsVarious statements in
this release concerning Jounce’s future expectations, plans and
prospects, including without limitation, Jounce’s expectations
regarding the timing, progress and results of preclinical studies
and clinical trials for Jounce’s product candidates and any future
product candidates; the timing, scope or likelihood of regulatory
filings and approvals; and Jounce’s ability to identify new targets
for additional product candidates, to develop future product
candidates and combination therapies, and to successfully
commercialize and market products may constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws and are subject to substantial risks, uncertainties
and assumptions. You should not place reliance on these forward
looking statements, which often include words such as “anticipate,”
“estimate,” “expect,” “intend,” “may,” “on track,” “plan,”
“predict,” “target,” “potential” or similar terms, variations of
such terms or the negative of those terms. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company cannot guarantee such
outcomes. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, as well as those risks more fully discussed in
the section entitled “Risk Factors” in Jounce’s most recent
quarterly report on Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in Jounce’s
subsequent filings with the U.S. Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Media Contact:
Katie Engleman
Pure Communications, Inc.
(919) 333-7722
katie@purecommunicationsinc.com
Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024